Axsome Therapeutics (AXSM) Tops Q4 EPS by 17c

Axsome Therapeutics (NASDAQ: AXSM) reported Q4 EPS of ($0.56), $0.17 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $195.99 million versus the consensus estimate of $189.81 million.

For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.

You May Also Be Interested In

• JPMorgan Upgrades Amber Enterprises India Ltd (AMBER:IN) to Overweight
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Jefferies Downgrades BSE Limited (BSE:IN) to Underperform